RE:RE:RE:RE:RE: "excellent" progress on early-stage pipelineI think the higher probability would be to have all of our pipeline programs advanced far enough so when we reach Clinical trials with 001 that we sell just the 001 program (even for 1 billion, so roughly $10 a share US) and keep the rest of the company. Another option would be to become a trust bank so to speak, were all Pharma's can license our technology but never aquire it. We would become a perpetual licensing machine.
Either way, yes we make boat loads of money. From where we are now it seems like big shoes to fill but if we ever start looking like we can fill them, look out...